CN101287706A — 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
Assigned to Takeda GmbH · Expires 2008-10-15 · 18y expired
What this patent protects
式I的化合物,其中R1、R2、R3、R4、R5、R6和R7具有说明书中所示的含义,及其盐是新型的有效HDAC抑制剂。更详细地说,本发明涉及选自(E)-(E)-N-羟基-3-(1-[4-(([2-(1H-吲哚-2基)-乙基]-甲基-氨基)-甲基)-苯磺酰基]-1H-吡咯-3-基)-丙烯酰胺、(E)-3-[1-(4-二甲基氨基甲基-苯磺酰基)-1H-吡咯-3-基]-N-羟基-丙烯酰胺和(E)-N-羟基-3-[1-(5-吡啶-2-基-噻吩-2-磺酰基)-1H-吡咯-3-基]-丙烯酰胺的化合物与盐酸的盐、它们的水合物,并涉及这些盐和水合物的结晶形式。
USPTO Abstract
式I的化合物,其中R1、R2、R3、R4、R5、R6和R7具有说明书中所示的含义,及其盐是新型的有效HDAC抑制剂。更详细地说,本发明涉及选自(E)-(E)-N-羟基-3-(1-[4-(([2-(1H-吲哚-2基)-乙基]-甲基-氨基)-甲基)-苯磺酰基]-1H-吡咯-3-基)-丙烯酰胺、(E)-3-[1-(4-二甲基氨基甲基-苯磺酰基)-1H-吡咯-3-基]-N-羟基-丙烯酰胺和(E)-N-羟基-3-[1-(5-吡啶-2-基-噻吩-2-磺酰基)-1H-吡咯-3-基]-丙烯酰胺的化合物与盐酸的盐、它们的水合物,并涉及这些盐和水合物的结晶形式。
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.